Skip to main content
main-content

Free registration

Medicine Matters was developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

16-04-2018 | Non-small cell lung cancer | News

Neoadjuvant nivolumab could benefit patients with resectable NSCLC

Neoadjuvant treatment with the PD-1 inhibitor nivolumab shows promising activity in patients with untreated surgically resectable early non-small-cell lung cancer, with few side effects, US researchers report.

SUMIT: Selumetinib in metastatic uveal melanoma

This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

11-04-2018 | Liquid biopsy | Themed collection | Collection

Liquid biopsy in oncology

This themed content collection highlights the role of liquid biopsy in the management of patients with solid tumors and evaluates the role of liquid biopsy in different types of cancer.

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from across the site

20-04-2018 | Pancreatic cancer | News

News in brief

Short-acting calcium channel blockers may increase pancreatic cancer risk

Postmenopausal women who take short-acting calcium channel blockers could be at increased risk for developing pancreatic cancer, findings indicate.

19-04-2018 | Non-small cell lung cancer | News

First-line pembrolizumab plus chemotherapy boosts advanced NSCLC outcomes

Adding pembrolizumab to standard chemotherapy significantly delays disease progression and improves overall survival in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer, KEYNOTE-189 data show.

Source:

AACR 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

19-04-2018 | Medullary thyroid carcinoma | News

Targeted inhibitor shows potential for RET-altered solid tumors

A selective inhibitor of the receptor tyrosine kinase RET could benefit patients with tumors harboring alterations in the oncogene, suggest early results presented at the American Association for Cancer Research Annual Meeting 2018.

Source:

AACR 2018; Chicago, Illinois, USA

18-04-2018 | Non-small cell lung cancer | News

Nivolumab plus ipilimumab benefits shown in highly mutated advanced NSCLC

CheckMate-227 shows that treatment with nivolumab plus ipilimumab significantly improves progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer and a high tumor mutational burden.

Source:

AACR 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

17-04-2018 | Melanoma | News

Pembrolizumab delays recurrence in high-risk stage III melanoma

Adjuvant pembrolizumab significantly improves recurrence-free survival, compared with placebo, when given to patients with high-risk stage III melanoma for up to 1 year, researchers report in The New England Journal of Medicine.

Source:

AACR 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

16-04-2018 | Lung cancer | Article

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde PA et al. N Eng J Med 2018. doi:10.1056/NEJMoa1716078

Latest from us on Twitter

Updates from oncology organizations

Meet our Editorial Board

New Content Item Meet our Advisory Board

image credits